GlassScriptPhysician profile
Krista Lippold
NPI 1841337417
$2,626.83
in general payments reported to CMS, 2019-2025
20 companies · $472 in 2025
The $472 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $143 · 2022: $545 · 2023: $816 · 2024: $651 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,939.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,938.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $408.45 | 2021-2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $287.49 | 2022-2025 | Lokelma, Airsupra |
| Amgen INC. | $232.48 | 2024-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $226.04 | 2023 | Watchman Flx, Watchman Access System |
| Abbvie INC. | $137.48 | 2023 | |
| Xeris Pharmaceuticals, INC. | $134.99 | 2023 | Gvoke Hypopen |
| Actelion Pharmaceuticals US, INC. | $125.00 | 2024 | Uptravi, Opsumit |
| Gilead Sciences, INC. | $122.11 | 2025 | Epclusa |
| Alnylam Pharmaceuticals INC. | $122.11 | 2023 | Givlaari |
| Organogenesis INC. | $116.16 | 2021-2022 | |
| Pfizer INC. | $110.05 | 2024 | |
| Neurelis, INC. | $110.01 | 2022 | |
| Neurocrine Biosciences, INC. | $92.26 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $88.21 | 2022 | |
| Abbott Laboratories | $71.05 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $70.00 | 2023 | |
| Medtronic, INC. | $54.17 | 2024 | Kyphon Express II Kyphopak Tray |
| Stryker Corporation | $49.76 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $44.55 | 2024 | |
| Dexcom, INC. | $24.46 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krista Lippold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.